Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-19T17:55:01.168Z Has data issue: false hasContentIssue false
  • English
  • Français

Focusing on drug versus disease mechanisms and on clinical subgrouping to advance personalised medicine in psychiatry

Published online by Cambridge University Press:  19 June 2013

Jose de Leon
Jose de Leon*
Affiliation:
University of Kentucky Mental Health Research Center at Eastern State Hospital, Lexington, KY, USA Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, Granada, Spain
*
Jose de Leon, UK Mental Health Research Center at Eastern State Hospital, 1350 Bull Lea Road, Lexington, KY 40511, USA. Tel: +(859) 246-8440; Fax: +(859) 246-8446; E-mail: jdeleon@uky.edu.
Get access Rights & Permissions [Opens in a new window]

Abstract

Personalised medicine has finally been featured in psychiatric journals, but psychiatrists have mainly focused on the promise of using disease mechanisms to personalise treatment. Psychiatric disorders such as schizophrenia and depression are not diseases, in the medical sense, and are probably more like syndromes. Instead of spending much time and effort focusing on the mechanisms of diseases that may instead be syndromes, the author believes that psychiatrists should (1) learn more about personalising prescription via drug mechanisms, a pharmacological approach to personalised medicine; and (2) reconsider prior attempts by traditional clinical psychopharmacologists to use sophisticated clinical approaches that try to subdivide psychiatric syndromes into groups that may be more homogenous for treatment response.

Keywords

Alzheimer diseaseindividualised medicinepharmacogeneticspharmacogenomicspsychopharmacology
Type
Perspective
Information
Acta Neuropsychiatrica , Volume 26 , Issue 6 , December 2014 , pp. 327 - 333
Copyright
© Scandinavian College of Neuropsychopharmacology 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Osborn, LA. Psychiatry and medicine: An introduction to personalized medicine. New York: McGraw Hill, 1952.Google Scholar
2.de Leon, J. Evidence-based medicine versus personalized medicine: are they enemies? J Clin Psychopharmacol 2012;32:153–164.Google Scholar
3.Garrod, AE. Inborn errors of metabolism. London: Oxford University Press, 1909.Google Scholar
4.Vogel, F. Moderne probleme der Humangenetik. Ergeb Inn Med Kinderheild 1959;12:52–125.Google Scholar
5.Kanigel, RApprentice to genius: the making of a scientific dynasty. New York: Macmillan Publishing Company, 1986.Google Scholar
6.Brodie, BB, Cosmides, GJ. Toxicology and the biomedical sciences. Science 1965;148:1547–1554.Google Scholar
7.Meyer, UA. Pharmacogenetics – five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004;5:669–676.Google Scholar
8.Fodor, SP. Massively parallel genomics. Science 1997;277:393–395.Google Scholar
9.Science. New research horizons. Science 1997;278:2039.Google Scholar
10.de Leon, J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res 2009;59:81–89.CrossRefGoogle ScholarPubMed
11.Hiemke, C, Baumann, P, Bergemann, Net al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011;44:195–235.Google Scholar
12.Crettol, S, de Leon, J, Hiemke, C, Eap, C. Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine. Clin Pharmacol Ther 2014;95:254–257.Google Scholar
13.de Leon, J, Spina, E, Diaz, FJ. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monitor 2013;35:30–47.Google Scholar
14.Wagner, JA. Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 2002;18:41–46.Google Scholar
15.Dienstmann, R, Rodon, J, Tabernero, J. Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategies. Am Soc Clin Oncol Educ Book 2012;32:168–172.CrossRefGoogle Scholar
16.Waldrop, M. Complexity: the emerging science at the edge of order and chaos. New York: Touchstone Books, 1992.Google Scholar
17.Barabási, AL, Gulbahce, N, Loscalzo, J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011;12:56–68.Google Scholar
18.McGorry, PD. Early clinical phenotypes, clinical staging, and strategic biomarker research: building blocks for personalized psychiatry. Biol Psychiatry 2013;74:394–395.Google Scholar
19.Weissman, MM, Brown, AS, Talati, A. Translational epidemiology in psychiatry: linking population to clinical and basic sciences. Arch Gen Psychiatry 2011;68:600–608.Google Scholar
20.Wong, EH, Fox, JC, Ng, MYet al. Toward personalized medicine in the neuropsychiatric field. Int Rev Neurobiol 2011;101:329–349.CrossRefGoogle ScholarPubMed
21.Heckers, S. Future in psychopathology research. Schizophr Bull 2014;40(Suppl. 2):S147–S151.Google Scholar
22.Ozomaro, U, Wahlestedt, C, Nemeroff, CB. Personalized medicine in psychiatry: problems and promises. BMC Med 2013;11:132.Google Scholar
23.de Leon, J, Armstrong, SC, Cozza, KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006;47:75–85.CrossRefGoogle ScholarPubMed
24.Arranz, MJ, de Leon, J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007;12:707–747.Google Scholar
25.Insel, TR, Scolnick, EM. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry 2006;11:11–17.Google Scholar
26.Kapur, S, Phillips, AG, Insel, TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry 2012;17:1174–1179.Google Scholar
27.McHugh, PR. Striving for coherence: psychiatry’s efforts over classification. JAMA 2005;293:2526–2528.Google Scholar
28.Lain Entralgo, P. Historia de la medicina. Barcelona: Salvat, 1978.Google Scholar
29.de Leon, J. Is psychiatry scientific? A letter to a 21st century psychiatry resident. Psychiatry Investig 2013;10:205–217.Google Scholar
30.de Leon, J. One hundred years of limited impact of Jaspers’ General Psychiatry in the US psychiatry. J Nerv Ment Dis 2014;202:79–87.Google Scholar
31.Berrios, GE. Alzheimer’s disease: a conceptual history. Int J Geriatr Psychiatry 1990;5:355–365.Google Scholar
32.de Leon, J. DSM-5 and research domain criteria: one hundred years after Jaspers’s General Psychopathology. Am J Psychiatry 2014 May.Google Scholar
33.Morley, JE. Alzheimer’s disease: future treatments. J Am Med Dir Assoc 2011;12:1–7.Google Scholar
34.Crenshaw, DG, Gottschalk, WK, Lutz, MWet al. Using genetics to enable studies on the prevention of Alzheimer’s disease. Clin Pharmacol Ther 2013;93:177–185.Google Scholar
35.Ban, TA. Neuropsychopharmacology and the forgotten language of psychiatry. International Network for the History of Neuropsychopharmacology (INHN) E-Book, 2013. http://inhn.org/previews/neuropsychopharmacology-and-the-forgotten-language-of-psychiatry.htmlGoogle Scholar
36.Andreasen, NC. DSM and the death of phenomenology in America: an example of unintended consequences. Schizophr Bull 2007;33:108–112.Google Scholar
37.Ban, TA. Prolegomenon to the clinical prerequisite: psychopharmacology and the classification of mental disorders. Prog Neuropsychopharmacol Biol Psychiatry 1987;11:527–580.Google Scholar
38.Ban, TA. Towards a clinical methodology for neuropsychopharmacological research. Neuropsychopharmacol Hung 2007;9:81–90.Google Scholar
39.Hoenig, J. The concept of schizophrenia: Kraepelin – Bleuler – Schneider. Br J Psychiatry 1983;142:547–556.Google Scholar
40.Leonhard, K. Classification of endogenous psychoses, 5th edn.New York: Irvington Publisher, 1979.Google Scholar
41.Astrup, C. Schizophrenia: conditional reflex studies. Springfield, IL: Thomas, 1962.Google Scholar
42.Fish, F. The influence of the tranquillisers on the Leonhard schizophrenic syndromes. Encéphale 1964;53:245–249.Google ScholarPubMed
43.Guy, W, Ban, TA, Wilson, WH. An international survey of tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:401–405.Google Scholar
44.Beckmann, H, Fritze, J, Franzek, E. The influence of neuroleptics on specific syndromes and symptoms in schizophrenics with unfavourable long-term course. A 5-year follow-up study of 50 chronic schizophrenics. Neuropsychobiology 1992;26:50–58.Google Scholar
45.Fibiger, HC. Psychiatry, the pharmaceutical industry, and the road to better therapeutics. Schizophr Bull 2012;38:649–650.Google Scholar
46.Stöber, G, Kohlmann, B, Iekiera, Met al. Systematic mutation analysis of KIAA0767 and KIAA1646 in chromosome 22q-linked periodic catatonia. BMC Psychiatry 2005;5:36.Google Scholar